The hypoxic tumor microenvironment characteristic of ccRCC may further amplify PLOD activity, as hypoxia-inducible factor (HIF) signaling pathways are known to specifically activate PLOD expression, potentially creating a therapeutic vulnerability (17). This evidence concerns the gene PLOD1 and nonpapillary renal cell carcinoma.